



Media Contact  
Dan McFadden  
[dmcfadden@oculusis.com](mailto:dmcfadden@oculusis.com)  
(425) 836-3103

## **OCULUS INNOVATIVE SCIENCES CLOSES SERIES "A" ROUND OF FINANCING FOR \$8 MILLION**

### **Non-toxic and disruptive Microcyn™ technology proving successful in numerous applications throughout Mexico as both a disinfectant and an antiseptic.**

**MORELIA, MX--(April 16, 2004)**— Oculus Technologies of Mexico, a subsidiary of Oculus Innovative Sciences of the United States, today announced that the company's first commercialized technology, the non-toxic Microcyn™ disinfectant and antiseptic, has received approval from the Mexican Ministry of Health as a disinfectant and antiseptic for Mexico's veterinarian market. The veterinarian Microcyn-based product, Vetericyn60™, is now available from the Latin American distributor, Quimica Pasteur, S. De RL.

The Mexican Ministry of Health approved Microcyn in July of 2003, allowing for the use of Microcyn as a commercial disinfectant for hard surfaces and medical devices, as well as an antiseptic for use on patients for the irrigation of wounds and in pre-operative skin preparation.

In March 2004, Oculus Innovative Sciences received CE mark approval for its Microcyn technology, which allows the company to release its product into the medical markets in Europe as a general disinfectant. Oculus has increased its manufacturing capacity worldwide in anticipation of further approvals in the U.S., Europe and the remainder of Latin America.

### **About Oculus Technologies of Mexico**

Oculus Technologies of Mexico, S.A. de C.V., located in Morelia, Michoacan, is a subsidiary of Oculus Innovative Sciences, headquartered in Petaluma, California. The company is pioneering innovative technologies and disruptive technologies that globally re-define the disinfectant and antiseptic markets. Oculus has developed the revolutionary Microcyn' disinfectant and antiseptic with broad applications in such diverse markets as consumer, medical, dental, veterinarian, cosmetic, wound healing, food processing and counter-bioterrorism. The company has employees and operations in Mexico, Europe and the U.S. The company's other wholly owned subsidiary is Oculus Innovative Sciences Netherlands B.V., which serves the European market. For more information, please visit

either of the Oculus web sites at [www.oculus.com.mx](http://www.oculus.com.mx) or [www.oculusis.com](http://www.oculusis.com).

**Forward-Looking Statements**

This press release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements relate to, among other things, plans and timing for the introduction of our products, statements about future market conditions, supply and demand conditions, revenues, gross margins, operating expenses, profits and other expectations, intentions and plans contained in this press release that are not historical fact. Our expectations as expressed in this press release depend upon our ability to develop, manufacture and supply products that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in the health sciences market. In light of the many risks and uncertainties surrounding this market, you should understand that we cannot assure you that the forward-looking statements contained in this press release will be realized.

**Disclaimer**

This release concerns a use that has not been approved or cleared by the Food and Drug Administration or the Environmental Protection Agency.